A study of Smad4, Smad6 and Smad7 in surgically resected samples of pancreatic ductal adenocarcinoma and their correlation with clinicopathological parameters and patient survival

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Singh, Puneet ^a   Srinivasan, Radhika ^a   Wig, Jai ^a   Radotra, Bishan ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

clinicopathological parameters; Pancreas; pancreatic adenocarcinoma; prognosis; Smad4; Smad6; Smad7

Indexed keywords

EID: 84155176716     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-560     Document Type: Review

References (29)

1. Mechanism of activation of the TGF-beta receptor. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J, Nature 1994 370 341 347 10.1038/370341a0 8047140
2. TGF-beta signal transduction. Massague J, Annu Rev Biochem 1998 67 753 791 10.1146/annurev.biochem.67.1.753 9759503 (Pubitemid 28411144)
3. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH, J Biol Chem 1997 272 28107 28115 10.1074/jbc.272.44.28107 9346966 (Pubitemid 27473621)
4. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, Shioda T, Roberts AB, Lechleider RJ, J Biol Chem 2000 275 2115 2122 10.1074/jbc.275.3.2115 10636916 (Pubitemid 30060840)
5. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ, Oncogene 1997 14 1891 1899 10.1038/sj.onc.1201017 9150356 (Pubitemid 27217802)
6. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA, Wrana JL, Falb D, Cell 1997 89 1165 1173 10.1016/S0092-8674(00)80303-7 9215638 (Pubitemid 127678749)
7. Smad6 inhibits signalling by the TGF-beta superfamily. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K, Nature 1997 389 622 626 10.1038/39355 9335505 (Pubitemid 27446182)
8. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Singh P, Srinivasan R, Wig JD, Pancreas 2011 40 644 652 10.1097/MPA.0b013e31821ff741 21673535
9. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. van Heek T, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, Wilentz RE, Am J Clin Pathol 2002 117 755 765 10.1309/5RQ0-JCQU-5XF2-51LQ 12090425 (Pubitemid 34457011)
10. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE, Science 1996 271 350 353 10.1126/science.271.5247.350 8553070
11. DPC4 gene in various tumor types. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, et al. Cancer Res 1996 56 2527 2530 8653691 (Pubitemid 26170688)
12. Molecular genetics and related developments in pancreatic cancer. Hruban RH, Goggins M, Kern SE, Curr Opin Gastroenterol 1999 15 404 409 10.1097/00001574-199909000-00006 17023981 (Pubitemid 29390428)
13. Tumor-suppressor genes in pancreatic cancer. Hruban RH, Offerhaus GJ, Kern SE, Goggins M, Wilentz RE, Yeo CJ, J Hepatobiliary Pancreat Surg 1998 5 383 391 10.1007/s005340050062 9931387 (Pubitemid 128662609)
14. The Smad family and its role in pancreatic cancer. Singh P, Wig JD, Srinivasan R, Indian J Cancer 2011 48 351 360 10.4103/0019-509X.84939 21921337
15. Tumor-node-metastasis staging of pancreatic adenocarcinoma. Katz MH, Hwang R, Fleming JB, Evans DB, CA Cancer J Clin 2008 58 111 125 10.3322/CA.2007.0012 18272835 (Pubitemid 351521866)
16. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Hua Z, Zhang YC, Hu XM, Jia ZG, World J Gastroenterol 2003 9 2764 2767 14669329 (Pubitemid 38054456)
17. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM, J Clin Oncol 2002 20 4531 4542 10.1200/JCO.2002.12. 063 12454109 (Pubitemid 35402956)
18. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Tascilar M, Offerhaus GJ, Altink R, Argani P, Sohn TA, Yeo CJ, Cameron JL, Goggins M, Hruban RH, Wilentz RE, Am J Clin Pathol 2001 116 831 837 10.1309/WF03-NFCE-7BRH-7C26 11764071 (Pubitemid 33108153)
19. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, et al. J Clin Oncol 2011 29 3037 3043 10.1200/JCO.2010.33.8038 21709185
20. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P, Br J Cancer 2011 104 1440 1451 10.1038/bjc.2011.110 21448172
21. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P, J Biol Chem 1998 273 29195 29201 10.1074/jbc.273.44.29195 9786930 (Pubitemid 28507620)
22. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M, Oncogene 1999 18 5363 5372 10.1038/sj.onc.1202909 10498890 (Pubitemid 29469224)
23. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M, Cancer Res 2004 64 3599 3606 10.1158/0008-5472.CAN-03-2999 15150118 (Pubitemid 38657938)
24. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, Buchler MW, Korc M, Friess H, Int J Mol Med 2006 17 761 767 16596258
25. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Kim YH, Lee HS, Lee HJ, Hur K, Kim WH, Bang YJ, Kim SJ, Lee KU, Choe KJ, Yang HK, Ann Oncol 2004 15 574 580 10.1093/annonc/mdh131 15033661 (Pubitemid 38559590)
26. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, Zhou ZH, Chen H, Wang K, Xu ZD, Liu LM, Ann Surg Oncol 2009 16 826 835 10.1245/s10434-008-0284-5 19165547
27. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Ellenrieder V, Buck A, Harth A, Jungert K, Buchholz M, Adler G, Urrutia R, Gress TM, Gastroenterology 2004 127 607 620 10.1053/j.gastro.2004.05.018 15300592 (Pubitemid 39091908)
28. Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. Boyer Arnold N, Korc M, J Biol Chem 2005 280 21858 21866 10.1074/jbc.M500583200 15811853 (Pubitemid 40827837)
29. A study on pancreatic cancer in Chennai (Madras), India. Gajalakshmi CK, Swaminathan R, Shanta V, Cancer Lett 1998 122 221 226 10.1016/S0304-3835(97) 00392-3 9464514 (Pubitemid 28058639)